Evidence map›Paper›PMID 33243224›Full record

ArticleMicrobial cell factories2020

Efficient protection of microorganisms for delivery to the intestinal tract by cellulose sulphate encapsulation.

Walter H Gunzburg, Myo Myint Aung, Pauline Toa, Shirelle Ng, Eliot Read, Wee Jin Tan, Eva Maria Brandtner, John Dangerfield, Brian Salmons

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Veterinary sciences · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Probiotic Potential ofMicroorganisms · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Microorganisms · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Walter H GunzburgAustrianova Singapore, 41 Science Park Road, #03-15 The Gemini, Singapore, 117610, Singapore. gunzburg@sgaustria.com.ORCID http://orcid.org/0000-0001-8907-1021
Myo Myint AungAustrianova Singapore, 41 Science Park Road, #03-15 The Gemini, Singapore, 117610, Singapore.
Pauline ToaAustrianova Singapore, 41 Science Park Road, #03-15 The Gemini, Singapore, 117610, Singapore.
Shirelle NgAustrianova Singapore, 41 Science Park Road, #03-15 The Gemini, Singapore, 117610, Singapore.
Eliot ReadAustrianova Singapore, 41 Science Park Road, #03-15 The Gemini, Singapore, 117610, Singapore.
Wee Jin TanAustrianova Singapore, 41 Science Park Road, #03-15 The Gemini, Singapore, 117610, Singapore.
Eva Maria BrandtnerAustrianova Singapore, 41 Science Park Road, #03-15 The Gemini, Singapore, 117610, Singapore.
John DangerfieldAustrianova Singapore, 41 Science Park Road, #03-15 The Gemini, Singapore, 117610, Singapore.
Brian SalmonsAustrianova Singapore, 41 Science Park Road, #03-15 The Gemini, Singapore, 117610, Singapore.
Singapore Science Park · SGUniversity of Veterinary Medicine Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGut microbiota in humans and animals play an important role in health, aiding in digestion, regulation of the immune system and protection against pathogens. Changes or imbalances in the gut microbiota (dysbiosis) have been linked to a variety of local and systemic diseases, and there is growing evidence that restoring the balance of the microbiota by delivery of probiotic microorganisms can improve health. However, orally delivered probiotic microorganisms must survive transit through lethal highly acid conditions of the stomach and bile salts in the small intestine. Current methods to protect probiotic microorganisms are still not effective enough.

resultsWe have developed a cell encapsulation technology based on the natural polymer, cellulose sulphate (CS), that protects members of the microbiota from stomach acid and bile. Here we show that six commonly used probiotic strains (5 bacteria and 1 yeast) can be encapsulated within CS microspheres. These encapsulated strains survive low pH in vitro for at least 4 h without appreciable loss in viability as compared to their respective non-encapsulated counterparts. They also survive subsequent exposure to bile. The CS microspheres can be digested by cellulase at concentrations found in the human intestine, indicating one mechanism of release. Studies in mice that were fed CS encapsulated autofluorescing, commensal E. coli demonstrated release and colonization of the intestinal tract.

conclusionTaken together, the data suggests that CS microencapsulation can protect bacteria and yeasts from viability losses due to stomach acid, allowing the use of lower oral doses of probiotics and microbiota, whilst ensuring good intestinal delivery and release.

Indexed as

AnimalsCell EncapsulationCellulaseCelluloseDrug CompoundingDrug Delivery SystemsEscherichia coliGastric JuiceGastrointestinal MicrobiomeHumansHydrogen-Ion ConcentrationIntestinesMaleMiceMice, NudeMicrobial ViabilityCellulaseCellulosecellulose sulfateAcid protectionCellulose sulphateEncapsulationGut microbiome dysbiosisLiving cell encapsulationMicrobiotaProbiotics

Identifiers

PMID33243224
PMCPMC7691082
OpenAlexW3110377174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.